구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | IFN-gamma |
Overview Company | National Institute of Allergy and Infectious Diseases (NIAID) |
Overview Modality | CGT |
Overview Target | IFN-Gamma Therapy |
Overview Indication | IFN-Gamma Therapy; CGD Gene Mutation |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Toxicology Major finding | Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.. Patients with metastatic high-grade serous ovarian carcinoma are often unresponsive to immunotherapies; here we identify salt-inducible kinases (SIKs) as key drivers of immunosuppression. Human T cells in the presence of patient ascites express high levels of SIK and the upstream kinase LKB1, whereas… |
Clinical Safety signal | Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.. Patients with metastatic high-grade serous ovarian carcinoma are often unresponsive to immunotherapies; here we identify salt-inducible kinases (SIKs) as key drivers of immunosuppression. Human T cells in the presence of patient ascites express high levels of SIK and the upstream kinase LKB1, whereas… |
Clinical Program phase | APPROVED |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | IFN-gamma |
Overview Company | National Institute of Allergy and Infectious Diseases (NIAID) |
Overview Modality | CGT |
Overview Target | IFN-Gamma Therapy |
Overview Indication | IFN-Gamma Therapy; CGD Gene Mutation |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
Toxicology Major finding | Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.. Patients with metastatic high-grade serous ovarian carcinoma are often unresponsive to immunotherapies; here we identify salt-inducible kinases (SIKs) as key drivers of immunosuppression. Human T cells in the presence of patient ascites express high levels of SIK and the upstream kinase LKB1, whereas… |
Clinical Safety signal | Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer.. Patients with metastatic high-grade serous ovarian carcinoma are often unresponsive to immunotherapies; here we identify salt-inducible kinases (SIKs) as key drivers of immunosuppression. Human T cells in the presence of patient ascites express high levels of SIK and the upstream kinase LKB1, whereas… |
Clinical Program phase | APPROVED |
추천 비교
추천 비교